Background Profound evidence substantiates significantly reduced risk of catheter-related infections with prophylactic use of rifampin-and clindamycin-impregnated silicone cath-
Introduction
Rifampin-and clindamycin-impregnated silicone catheters (Bactiseal®) for external ventricular drainage (EVD) were developed to prevent cerebrospinal fluid (CSF) infections. Various studies, including a prospective, randomized, controlled trial [13] , have shown a significantly reduced risk of catheter-related infections with the use of Bactiseal-EVD (B-EVD) [6, 8, 13] . Standard therapy with nonantibiotic-impregnated EVD is known to have a high rate of infection (5-20%) [2, 4-6, 9-11, 13] . Standard treatment of CSF infection following EVD or VP shunt placement consists of removal and/or exchange of the catheter and broadspectrum intravenous antibiotic agents until verification of cultures [7] . Despite extensive data on the efficacy of B-EVD in the prevention of CSF infections, it is still not clearly defined whether B-EVD is beneficial after a CSF infection has occurred.
The aim of our study was to analyze the efficacy of B-EVD compared to standard non-antibiotic-impregnated EVD in the treatment of EVD-and VP-shunt-related ventriculitis.
Methods
We Patients in both groups received broad-spectrum intravenous antibiotics until the microorganisms were identified in cultures and the antibiogram results were completed. The antibiotic regimen was then specifically targeted until cultures were negative and clinical parameters of infection were in a normal range.
The following data were acquired for statistical analyses: demographic and clinical data, hospitalization time, time until remission of the infection parameters, detection of new bacterial resistance after insertion of a B-EVD on antibiograms, and clinical outcome using the mRS. Patients with incomplete patient records and patients with initial Gramnegative infections were excluded from the analysis, since B-EVD is ineffective in treating Gram-negative infections.
Analysis of the final data set was performed using JMP software (SAS Institute Inc., Cary NC, USA). Values were expressed as mean ± SD. A p value <0.05 was considered significant.
Results
Twenty-five patients (13 male, 12 female) were included in the study (15 in group 1, ten in group 2). The mean ages in groups 1 and 2 were 51.5±11.4 years and 50±19.8 years, respectively. Patients in group 1 underwent ventriculostomy for EVD due to subarachnoid hemorrhage (n=6), normal pressure hydrocephalus (n=2), intraventricular hemorrhage (n=1) and congenital hydrocephalus (n=1). EVD became necessary in group 2 due to subarachnoid hemorrhage (n= 10), normal pressure hydrocephalus (n=2), congenital hydrocephalus (n=2) and obstructive hydrocephalus (n=1).
We observed that time to remission of pleocytosis was significantly longer in group 1 (8±3.8 days) than in group 2 (5.1±1.8 days) (p<0.05). The polymorphonuclear cells decreased below 50% of peak value significantly faster in group 1 than in group 2 (4.1±2.9 vs. 5.8±1.6 days; p<0.05). There were no significant differences between group 1 and group 2 for the time until plasma neutrophil remission (5.7± 2.6 vs. 5.3±3.2 days) and for the time until C-reactive protein (CRP) dropped below 10 mg/l (4.2±3.5 vs. 5.6± 3.3 days). An overview of the course of laboratory infection parameters in both groups is given in Table 1 .
The length of hospitalization from the diagnosis of EVD-related ventriculitis until discharge was 28±12.5 days in group 1 and 35±19.4 days in group 2 (n.s.). The mRS of both groups was 2 ( Table 2) . The analysis of the clinical data and antibiograms for the B-EVD revealed no development of new antibiotic resistance.
Discussion
CSF infections, i.e., meningitis and ventriculitis, are the most common complications caused by EVD and VP shunts [4] . They are associated with increased morbidity, mortality, and hospitalization time [13] . Concerns regarding the risks of CSF infection have led to widespread use of prophylactic antibiotic agents in the treatment of patients with EVD catheters. It has been shown that prophylaxis with a single broad-spectrum antibiotic agent (cefepime) was an effective alternative to dual-specific antibiotic treatment with ampicillin/sulbactam and aztrenam for patients with an EVD in situ [12] . An additional study demonstrated almost identical rates of CSF infection in patients who received prophylactic antibiotics throughout the period the EVD catheter was in place (3.8%) compared to patients who received only periprocedural antibiotics (4%) [1] . However, evidence-based guidelines for prophylactic antibiotic (PAB) administration do not yet exist, and the effectiveness of PAB was not proven in a randomized, placebo-controlled, multicenter, double-blind study [7] . Given the clinical results with central line catheters impregnated with antibiotic agents [3] and the lack of data on PAB effectiveness, clinical trials with impregnated EVD catheters were conducted. It has been shown that with prophylactic use of B-EVD, risk of catheter-related infections can be significantly reduced [6, 13] . The standard treatment for CSF infections due to EVD or VP shunt insertion is changing the drainage system and treatment with antibiotic agents. To date, there is no study comparing insertion of B-EVD with non-antibioticimpregnated EVD in the management of EVD-or VP-shuntassociated CSF infection.
In the presented study, we analyzed the efficacy of B-EVD compared to standard EVD in the course of iatrogenic ventriculitis (EVD-related infections, VP shunt infections). One would expect greater efficacy using B-EVD, since it has been proven to significantly reduce catheter-related infections. Surprisingly, our study demonstrated no significant differences in the efficacy of treatment with B-EDV and standard EVD, in terms of parameters related to the course of infection (with the exception of remission of pleocytosis), hospitalization time, and outcome.
Despite the limited number of patients, our study suggests that there is limited benefit in using B-EVD for the management of iatrogenic ventriculitis. Additionally, in the B-EVD group, the period until normalization of CSF pleocytosis is significantly longer (p<0.05), suggesting that the duration of the infection is not shortened by B-EVD. All other infection parameters analyzed (time of plasma neutrophil remission, decrease in polymorphonuclear cells below 50% of peak value, and time until CRP dropped below 10 mg/l) showed no significant difference. The hospitalization time of patients treated with B-EVD tends to be shorter, but not significantly.
The costs of B-EVD exceed those of standard EVD by 44.1%. In addition, the hospitalization time of patients treated with B-EVD tends to be shorter (mean hospitalization time B-EVD group 28±12.5, standard EVD group 35± 19.4 days), but not significantly. Therefore, we assume that the usage of B-EVD in the management of iatrogenic ventriculitis might not have an economical advantage compared to standard EVD.
Antimicrobial resistance is an issue of potential concern with the use of impregnated catheters. Although there is no evidence that such resistance has resulted from central venous line catheters, continued surveillance for antibiotic resistance is required [3, 13] . None of the patients in our study treated with B-EVD showed new antibiotic resistance.
In conclusion, this retrospective pilot study indicates that B-EVD has no major advantage over non-antibioticimpregnated catheters in the management of EVD-related ventriculitis. Based on these findings, the indication for use of B-EVD remains prevention rather than management of EVD-associated infections. Prospective randomized clinical trials are warranted to further evaluate the effect of B-EVD in the management of iatrogenic ventriculitis.
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